Market Trends of Global Biopsy Devices Industry
This section covers the major market trends shaping the Biopsy Devices Market according to our research experts:
Needle-based Biopsy Instruments is Expected to Hold a Major Share in the Biopsy Devices Market
Needle-based biopsy holds the leading share in the market due to the increasing demand for these instruments that acquire samples from soft tissues of internal organs, such as breasts, kidneys, and lungs. This is poised to contribute to the growth of the overall market during the forecast period.
According to the Globocan 2020, the incidence of breast cancer in 2020 was 2,261,419, and the mortality due to breast cancer was 684,996 across the world. Furthermore, according to the same source, breast cancer is the most common among all the cancer types. The rising incidence and mortality of cancers such as breast cancer led to higher adoption of needle-based biopsy instruments for the testing of breast cancers, thereby representing the highest growth of this segment.
In addition, rising research on needle-based biopsy devices to bring smart biopsy devices in the market is further expected to drive the growth of this segment. For instance, in 2019, Dune Medical devices completed the first in-man cases for smart biopsy devices utilizing miniaturized sensors located on a core needle. Its percutaneous soft tissue biopsy device leverages the real-time tissue characterization capability of its radio-frequency (RF) spectroscopy technology.
Therefore, rising incidence of breast cancers and increasing demand for the needle-based biopsy instruments for acquiring the samples of soft tissues are the factors that are expected to drive this segment growth.
North America Holds the Largest Share and is Expected to Follow the Same Trend Over the Forecast Period
North America is the leading revenue contributor in the market. The established market players in the region will continue to account for a substantial share of the market throughout the forecast period. The number of biopsies performed in the United States is also found to be the highest, helping in the expansion of the overall market. The American Cancer Society's 2020 report estimated that about 60,530 new cases of leukemia and approximately 23,100 deaths from leukemia were expected to occur in the United States in 2020. Furthermore, sophisticated healthcare infrastructure and the growing prevalence of infections will positively impact the biopsy devices' growth over the projected timeframe.
Furthermore, a strong foothold of key players in the United States is further expected to drive the growth of the biopsy market in this region. Key market players such as Danaher, Beckton Dickinson, Hologic, Cook Medical, and Boston Scientific launch their products in the United States, which will lead to higher adoption of these devices in this region.
